Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms

Platelets from patients with myeloproliferative neoplasms (MPNs) exhibit a hyperreactive phenotype. Here, we found elevated P-selectin exposure and platelet-leukocyte aggregates indicating activation of platelets from essential thrombocythemia (ET) patients. Single cell RNA-seq analysis of primary samples revealed significant enrichment of transcripts related to platelet activation, mTOR and oxidative phosphorylation (OXPHOS) in ET patient platelets. These observations were validated via proteomic profiling. Platelet metabolomics revealed distinct metabolic phenotypes consisting of elevated ATP generation, accompanied by increases in the levels of multiple intermediates of the tricarboxylic acid (TCA) cycle, but lower alpha-ketoglutarate (α-KG) in MPN patients. Inhibition of PI3K/AKT/mTOR signaling significantly reduced metabolic responses and hyperreactivity in MPN patient platelets, while α-KG supplementation markedly reduced oxygen consumption and ATP generation. Ex vivo incubation of platelets from both MPN patients and Jak2 V617F mice with α-KG significantly reduced platelet activation responses. Oral α-KG supplementation of Jak2 V617F mice decreased splenomegaly and reduced hematocrit, monocyte and platelet counts. Finally, α-KG incubation significantly decreased proinflammatory cytokine secretion from MPN CD14+ monocytes. Our results reveal a previously unrecognized metabolic disorder in conjunction with aberrant PI3K/AKT/mTOR signaling, contributing to platelet hyperreactivity in MPN patients.

[1]  G. Ayers,et al.  PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in patients with Myelofibrosis. , 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  T. Barbui,et al.  Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment , 2022, Research and practice in thrombosis and haemostasis.

[3]  J. Marinković,et al.  Correlation between leukocyte‐platelet aggregates and thrombosis in myeloproliferative neoplasms , 2021, International journal of laboratory hematology.

[4]  S. Bhattacharyya,et al.  α-Ketoglutarate Inhibits Thrombosis and Inflammation by Prolyl Hydroxylase-2 Mediated Inactivation of Phospho-Akt , 2021, EBioMedicine.

[5]  G. Challen,et al.  Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition , 2021, Blood advances.

[6]  J. Zehnder,et al.  Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms , 2021, Cell reports. Medicine.

[7]  Jared S. Fowles,et al.  DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression , 2021, bioRxiv.

[8]  Jared S. Fowles,et al.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms , 2021, Frontiers in Immunology.

[9]  A. Kelleher,et al.  The Role of ZEB2 in Human CD8 T Lymphocytes: Clinical and Cellular Immune Profiling in Mowat–Wilson Syndrome , 2021, International Journal of Molecular Sciences.

[10]  M. Elvers,et al.  The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. , 2021, Blood.

[11]  M. Vitale,et al.  Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants , 2020, Cells.

[12]  Kenneth L. Jones,et al.  ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes , 2020, JCI insight.

[13]  G. Lippi,et al.  Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[14]  Á. Vicente,et al.  Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia , 2020, Frontiers in Immunology.

[15]  Kimberly A. Thomas,et al.  Metabolic phenotypes of standard and cold‐stored platelets , 2019, Transfusion.

[16]  Chen-Yu Liao,et al.  Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice , 2019, bioRxiv.

[17]  M. Gassmann,et al.  JAK2 mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. , 2019, Blood.

[18]  Robert A. Campbell,et al.  TNF-alpha driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. , 2019, Blood.

[19]  P. Heller,et al.  Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms , 2019, Front. Immunol..

[20]  Jiandong Chen,et al.  Interaction between p53 N terminus and core domain regulates specific and nonspecific DNA binding , 2019, Proceedings of the National Academy of Sciences.

[21]  N. Siritanaratkul,et al.  A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms , 2019, BMC Cancer.

[22]  E. Engle,et al.  Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling , 2019, Leukemia.

[23]  A. D’Alessandro,et al.  High-Throughput Metabolomics: Isocratic and Gradient Mass Spectrometry-Based Methods. , 2019, Methods in molecular biology.

[24]  J. Sáez-Rodríguez,et al.  Benchmark and integration of resources for the estimation of human transcription factor activities , 2018, bioRxiv.

[25]  T. Barbui,et al.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion , 2018, Blood Cancer Journal.

[26]  J. Teruya-Feldstein,et al.  JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition , 2018, The Journal of clinical investigation.

[27]  R. Xie,et al.  Platelet mitochondrial dysfunction and the correlation with human diseases. , 2017, Biochemical Society transactions.

[28]  T. Weichhart,et al.  mTORC1 and mTORC2 as regulators of cell metabolism in immunity , 2017, FEBS letters.

[29]  G. Pinkus,et al.  GATA1 Is a Sensitive and Specific Nuclear Marker for Erythroid and Megakaryocytic Lineages , 2017, American journal of clinical pathology.

[30]  M. Gladwin,et al.  Platelets from pulmonary hypertension patients show increased mitochondrial reserve capacity. , 2017, JCI insight.

[31]  G. Nolan,et al.  Mass Cytometry Analysis Reveals Hyperactive NF Kappa B Signaling in Myelofibrosis and Secondary Acute Myeloid Leukemia , 2016, Leukemia.

[32]  W. Miller,et al.  Megakaryocyte Polyploidization and Proplatelet Formation in Low-Attachment Conditions. , 2016, Biochemical engineering journal.

[33]  S. Zucker,et al.  Targeting glutamine metabolism in myeloproliferative neoplasms. , 2015, Blood cells, molecules & diseases.

[34]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[35]  W. Vainchenker,et al.  Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. , 2014, Blood.

[36]  P. Guglielmelli,et al.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. , 2014, Blood.

[37]  Sunia,et al.  The metabolite alpha-ketoglutarate extends lifespan by inhibiting the ATP synthase and TOR , 2014 .

[38]  A. Green,et al.  JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. , 2013, Blood.

[39]  S. Tamura,et al.  The basis examination of leukocyte–platelet aggregates with CD45 gating as a novel platelet activation marker , 2013, International journal of laboratory hematology.

[40]  Qiang Wen,et al.  AKT is a therapeutic target in myeloproliferative neoplasms , 2013, Leukemia.

[41]  N. Jing,et al.  Signal Transducer and Activator of Transcription 3 (STAT3) Regulates Collagen-Induced Platelet Aggregation Independently of Its Transcription Factor Activity , 2013, Circulation.

[42]  S. Sultana,et al.  Ameliorative potential of alpha-ketoglutaric acid (AKG) on acute lung injuries induced by ammonia inhalation in rats , 2012, Experimental lung research.

[43]  T. Barbui,et al.  Platelet‐induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera , 2011, American journal of hematology.

[44]  V. Ugo,et al.  Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. , 2010, Thrombosis research.

[45]  T. Barbui,et al.  Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms , 2010, Thrombosis and Haemostasis.

[46]  Jun Xu,et al.  Oligomycin-induced Bioenergetic Adaptation in Cancer Cells with Heterogeneous Bioenergetic Organization , 2010, The Journal of Biological Chemistry.

[47]  V. Appanna,et al.  α-Ketoglutarate Dehydrogenase and Glutamate Dehydrogenase Work in Tandem To Modulate the Antioxidant α-Ketoglutarate during Oxidative Stress in Pseudomonas fluorescens , 2009, Journal of bacteriology.

[48]  P. Flevaris,et al.  Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. , 2009, Blood.

[49]  A. Falanga,et al.  Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia , 2008, Haematologica.

[50]  N. Villamor,et al.  Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis , 2008, Annals of Hematology.

[51]  M. Weiss,et al.  STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice. , 2007, The Journal of clinical investigation.

[52]  I. Ford,et al.  Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies , 2007, Journal of thrombosis and haemostasis : JTH.

[53]  N. Villamor,et al.  Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. , 2006, Haematologica.

[54]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[55]  P. Perrotta,et al.  Platelets express steroidogenic 17beta-hydroxysteroid dehydrogenases. Distinct profiles predict the essential thrombocythemic phenotype. , 2005, Thrombosis and haemostasis.

[56]  T. Barbui,et al.  Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. , 2005, Experimental hematology.

[57]  N. Hay,et al.  Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. , 2004, Blood.

[58]  M. Jensen,et al.  Increased circulating platelet–leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count , 2001, European journal of haematology.